Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 42, Issue 1, Pages 74-77Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyr166
Keywords
gastric; neoadjuvant chemotherapy; Phase II; cancer
Categories
Funding
- Kanagawa Standard Anti-cancer Therapy Support System (KSATTS)
Ask authors/readers for more resources
This randomized Phase II trial will compare the outcome of neoadjuvant chemotherapy using two and four courses of S-1 plus cisplatin or S-1 plus cisplatin plus docetaxel by a two-by-two factorial design for patients with macroscopically resectable serosa-positive gastric cancer. After neoadjuvant chemotherapy, patients will receive D2 gastrectomy followed by S-1 chemotherapy for 1 year postoperatively. The primary endpoint is the 3-year overall survival. The sample size is 120 for the two hypotheses: the superiority of four courses compared with two courses and the superiority of S-1 plus cisplatin plus docetaxel compared with S-1 plus cisplatin. This trial will be able to define the more suitable number of cycles and better regimen of neoadjuvant chemotherapy for gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available